Rezum water vapour therapy: promising early outcomes from the first UK series

Abstract

The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MISTs). These provide an attractive option for men looking for meaningful improvement in urinary symptoms, whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.

Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study

“…In contrast to some of the other MIST such as Urolift and urethral stents, Rezūm can be also used for enlarged median lobes [18]. In contrast to Aquablation and as prostate artery embolization (PAE), the Rezūm system has demonstrated to be successful in the day-case setting and this is relevant in the COVID-19 era, where the need to further reduce theater time and hospital stay is extremely important [19][20][21][22][23]. Moreover, the treatment time is short with procedures performed in office or outpatient setting thereby reducing the overall cost allowing high patient turnover.…”

Emerging Data on the Safety and Efficacy of Transurethral Water Vapour Therapy for Benign Prostatic Hyperplasia

“…Three further studies have reported greater than 30% reduction in prostate volume. 12 , 16 , 17 The lack of specimen retrieval does represent a disadvantage of Rezum and as a consequence no histopathological analysis is possible. Little is known currently regarding interpretation of PSA values post Rezum treatment in regard to evaluation for possible prostate cancer.…”

“…To date there have been 12 studies published on Rezum, which have included 1391 patients (mean age 68.7 years, range: 46-90) (Tables 1 and 2). [9][10][11][12][13][14][15][16][17][18][19][20] Over half of these studies (n=7) have been published in the past 2 years, reflecting the increasing interest and uptake of this novel intervention. There has only been one randomized study and the remainder represent cohort studies (5x retrospective and 6 x prospective).…”

“…Seven of these studies were performed in a multi-center setting. [10][11][12]14,17,18 The randomized study used a sham procedure as a comparator.- 14 This consisted of rigid cystoscopy with simulated active treatment sound effects. Across the studies, the mean prostate volume was 61.6 cc (range: 19.5-183).…”

“…Three further studies have reported greater than 30% reduction in prostate volume. 12,16,17 The lack of specimen retrieval does represent a disadvantage of Rezum and as a consequence no histopathological analysis is possible.…”